For Referring Providers

The UCSF Center for Neuroendocrine Tumors is designed to be a central hub for NET/NEC referrals of all types.

A new patient navigator will evaluate cases and direct them to appropriate providers. When feasible, same-day evaluation will be scheduled in multiple disciplines, such as surgery and medical oncology. Our new patient navigators may also refer directly to relevant disease-specific providers—for example, a urologic oncologist for a patient with prostate NEC.   Our new patient navigators may also refer directly to relevant disease-specific providers—for example, a urologic oncologist for a patient with prostate NEC.

Working with referring providers, our goal is to offer personalized, coordinated, multidisciplinary care for NET patients throughout their experience. In addition to formal review of biopsy material and imaging studies taken elsewhere, we can take advantage of the depth of expertise at UCSF as we address this complex group of diseases.

As needed, we can access specialty care (for example, endocrinology, cardiology or gastroenterology), early phase clinical trials (through the disease groups or, for example, the Cancer Immunotherapy Clinic) and a comprehensive menu of supportive care services (including symptom management services, psycho-oncology, nutrition resources and financial guidance). If appropriate, we can employ the UCSF500 molecular diagnostic test for analyzing tumor-associated mutations, which may lead to identifying additional therapeutic strategies.


Conditions treated:

  • Pancreatic NETs
  • Well-differentiated tumors of the GI tract (stomach, small intestine, appendix, colon and rectum), kidney, ovaries and presacral space, as well as unknown primary NETs
  • Bronchial carcinoid
  • Thymic carcinoid
  • Small cell lung carcinoma
  • Large cell NEC of lung
  • Other poorly differentiated NECs (small and large cell NECs)
  • Well differentiated G3 NETs
  • Neuroendocrine prostate cancer (NEPC)
  • Merkel cell carcinoma
  • Paraganglioma/Pheochromocytoma
  • Adrenal Cortical Carcinoma
  • Medullary Thyroid Carcinoma
  • Mixed tumors (adenoneuroendocrine carcinomas, mixed acinar-neuroendocrine tumors, globlet cell carcinoid)

If you prefer, you may contact the following associated clinics for disease groups and disciplines directly: